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Table 1
Multivariate OS Analysis
Total Cohort HR
95% CI P
50-59 Years
HR 95% CI P
60-73 Years
HR 95% CI P
STANDARD
VARIABLES
Age >60 1.83 1.26-
2.65
.001
HCT-CI >¼3 1.56 1.07-
2.28
.02 1.50 .88-
2.53
.13 1.72 .99-
2.98
.05
Active Disease 1.31 .90-
1.90
.16 1.54 .92-
2.58
.10 1.27 .71-
2.27
.42
Ablative
Regimen
1.54 1.02-
2.31
.04 2.14 1.24-
3.69
.01 1.07 .54-
2.10
.85
GA VARIABLES
IADL
Impairment
2.38 1.59-
3.56
<.001 1.86 1.07-
3.24
.03 3.25 1.75-
6.05
<.001
Slow Walk
Speed
1.80 1.14-
2.83
.01 1.16 .60-
2.28
.66 3.27 1.68-
6.39
.001
Reduced
Mental
Health
1.67 1.13-
2.48
.01 1.55 .92-
2.62
.10 1.87 1.01-
3.49
.04
Low Albumin 1.52 .94-
2.46
.09 1.23 .57-
2.63
.60 2.62 1.26-
5.47
.01
High CRP 2.51 1.54-
4.09
<.001 1.89 .94-
3.79
.07 3.13 1.52-
6.46
.002
*Each GA measure analyzed separately, adjusting for standard variables
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(age, HCT-CI, conditioning regimen intensity, disease risk).
Results: 203 adults >¼50 years completed GA and under-
went HCT.Mean agewas 59 years (range 50-73); 45% had high
disease risk, 76% received reduced intensity conditioning, and
14% underwent cord blood HCT. With median follow-up of 36
months, IADL limitations (P < 0.0001), slow walk speed (P ¼
0.01), low SF36-MCS (P¼ 0.01), and high CRP (P<0.001) were
signiﬁcantly associated with inferior OS, independent of
standard HCT variables. The prognostic effect of these GA
variables was greater in older recipients (Table 1). We then
created a simple risk score with 1 point for the most prog-
nostic functional measure (IADL impairment) and 1 point for
comorbidity (HCT-CI >¼3). This signiﬁcantly stratiﬁed out-
comes, particularly in those 60 years, such that 2-year OS
was 63%, 29%, and 0% for 0, 1, and 2 points, respectively.
Conclusion: GA measures confer independent prognostic
utility in older HCT recipients, especially in those >¼60
years. Implementation of GA prior to HCT may aid in
appropriate selection of older adults for HCT.
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Background: Recent studies have shown the intravenous
administration of high-dose cyclophosphamide (CY) in the
early post-transplant period to be a strategy for GvHD
prophylaxis in patients with hematologic malignancies who
receive allogeneic marrow grafts from alternative donors.
We evaluated the outcomes of patients who received
HPC-Apheresis products to compare the impact of post-
transplant CY on neutrophil engraftment, hematopoietic
chimerism, and early immune reconstitution in patients who
received post-HSCT CY following haplo-identical (HAP),matched unrelated donor (MUD), andmismatched unrelated
donor (mMUD) grafts vs. with conventional matched related
donor (MRD) graft recipients.
Methods and Results: We transplanted 44 patients (median
age, 49 years; range, 20-72 years) with advanced hemato-
logic malignancies n¼8 (HAP); 14 (MRD); 17 (MUD); 5
(mMUD). All patients received conditioning regimens based
on busulfan or total body irradiation (TBI). High-dose CY
(50mg/kg/day) was administered on days 3 and 4 following
HAP and on day 3 following MUD transplant. Peripheral
blood lymphocyte reconstitution and quantitative T-cell and
myeloid speciﬁc donor chimerism (STR) status was assessed
on post-HSCT days 30 and 60. Mean time to ANC 500 was
12.5 days for MRD, mMUD and MUD graft recipients. HAP
recipients took slightly longer at 15.2 days but not signiﬁ-
cantly different from others. Day +30 median CD3/CD15
chimerism was 82.3+12.4/99.8+0.5 for MRD; 86.7+16.0/
97.6+2.2 for MUD; 87.6+15.3/99.8+0.4 for mMUD; and
98.8+1.8/99.2+1.2 for HAP. Day +30 HAP CD3 chimerism was
signiﬁcantly improved over MRD (p<0.001) but not over
MUD or mMUD. CD15 chimerism did not differ between
groups. Of 30 patients that received CY, 18(60%) and 27(90%)
achieved full (>95%) donor CD3+ and CD15+chimerism by
day +30, respectively vs. 1 (7%) and 12 (86%) in 16 patients
who underwent MRD transplants. Day +30 total T cell
recovery was signiﬁcantly faster in MRD than CY-treated
recipients (p¼0.015) due principally to more robust CD8+ T
cell recovery. CD4 T cell recovery remained incomplete in all
groups through day +100. Recovery of gd T cells did not differ
between groups. Regulatory T cells are virtually absent. NK
cells recover to normal numbers at day +28 in all groups.
Conclusions: Recipients of HAP, MUD andmMUD grafts who
received post-HSCT CY show similar engraftment kinetics as
those who receive MRD grafts with standard immunosup-
pression. T-cell engraftment appears to follow myeloid
engraftment in those who received post-transplant CYand is
generally earlier by day 30 than in MSD graft recipients,
although CD3+CD8+ recovery is greater in MRD recipients
than others. Taken together, HPC-Apheresis is a reasonable
alternative donor graft source when accompanied by post-
HSCT CY-based GvHD prophylaxis.29
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Background: Haploidentical stem cell transplantation
(HaploSCT) using post-transplant cyclophosphamide (PTCY)
has been performed primarily with non-myeloablative con-
ditioning. We are exploring a melphalan-based, myeloa-
blative yet reduced-intensity conditioning (RIC), in an
ongoing phase II clinical trial.
Methods: Outcomes of the ﬁrst 84 pts treated after 01/2009
are reported. 47(56%) pts were males. 74 (88%) pts had their
ﬁrst transplant, 10 (12%) as second transplant. The median
age was 46 years (range 19-67). 57 (67.9%) pts were protocol
Table 1
Outcomes
overall
All
patients
(N¼84)
(%)
Myeloid in CR
(N¼27) (%)
ALL
(N¼10)
(%)
Lymphoma/
CLL
(N¼14) (%)
P
NRM 25.7 8.9 33.3 25.0 0.17
Relapse Rate 32.0 24.3 25.0 21.4 0.96
PFS 42.3 66.8 41.7 53.6 0.22
aGVHD II-IV 32.6 26.9 50.0 35.7 0.46
aGVHD III-IV 7.8 0 37.5 7.1 0.0038
cGVHD
Lim.+Ext.
21.3 21.7 57.1 17.9 0.11
cGVHD Ext.
only
10.2 17.7 17.1 0 0.36
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140mg/m2 with ﬂudarabine, +/- thiotepa previously
described by us (Ciurea SO, BBMT 2012;18:1835). All had a
bone marrow graft except 4 pts (95%). Diagnoses were AML/
MDS 49 (58.3%), CML 9 (11%), ALL 10 (12%), and lymphoma/
CLL 13 (15%) (4 Hodgkin’s, 4 NHL, 5 CLL), other 3 (3.6%). 28/46
(61%) pts with myeloid diseases were in CR at transplant, and
15/21 pts with AML in remission had poor-risk cytogenetics.
Donors were siblings (N¼36), children (N¼35), parents
(N¼12), cousin (N¼1).
Results: All pts achieved engraftment except 3 (96.4%), 91.6%
with full donor chimerism. Median time to neutrophil
engraftment was 18 days (11-43 days). The cumulative inci-
dence of acute and cGVHD for different groups is presented
in Table 1. Overall, for the entire cohort, the NRM was 25.7%,
relapse rate was 32% and PFS was 42.3%. The median OS for
ﬁrst transplants was 25.6months (mo) and 6.5mo for second
transplant pts. For pts receiving their ﬁrst transplant, PFS was
similar for those who received full and RIC. Of the 49 pts who
had ﬁrst transplant for AML/MDS, 27 (55.1%) were in
complete remission prior to transplant. NRM for these pts
was 9%, relapse rate 24.3% and PFS 66.8% at 50 mo of median
follow-up (Table 1, Figure 1B).
Conclusions: Melphalan-based conditioning for HaploSCT
offers good disease control with low treatment-related
mortality. Factors associated with survival were protocol
eligibility and remission status for myeloid diseases while
the melphalan dose did not impact outcomes. A low relapse
rate was observed for lymphoma/CLL pts.
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As the use of hematopoietic cell transplantation (HCT) in
older patients has increased over the past decade, so too have
donations from their older siblings. Prospective data
addressing the experiences of older donors are limited,
though such donors are more likely than younger donors to
have comorbidities, and are often motivated to give in spite
of potential risks. To address this lack of data, the NHLBI-
funded Related Donor Safety Study (RDSafe) prospectively
enrolled related donors of all ages between 2010-2013 at 54
transplant centers in the United States, assessed their pre-
donation comorbidities and health status, and followed them
for 1 year after donation, collecting detailed information on
pain levels and 12 additional frequently noted symptoms,
e.g., nausea, vomiting, insomnia. This report describes early
experiences of 256 donors age >60.
Results: At baseline there were high rates of pre-G-CSF pain
and symptoms in older donors, with 28% experiencing
grades 1-3 pain and 17% grades 1-3 symptoms (baseline rates
from earlier NMDP data for 41-60 year olds were 9% and 5%,
respectively, with no grade 3 or greater). Peak rates of all
grades of pain and symptoms at day 5 of G-CSF (day 1 of
collection) were 69% and 49%, respectively (see ﬁgure). Of
note, 11% experienced grades 3-4 pain; in contrast, for 41-60
year old NMDP donors, 89% experienced any grade pain; 3%,
grade 3-4 pain. Assessment at 1 month showed that 68% and
78% of older donors had returned to baseline pain and other
symptom levels while 16% and 6% still reported grade 2-3
pain and symptoms, respectively (NMDP recovery: 96% at 1
month for both). Univariate analysis of the effect of gender,
race, age, and baseline rates of pain and symptoms on G-CSF-
related pain and symptoms, and return to baseline at one
month was performed. Donors with grade 2-3 pain at. PFS for myeloid patients in remission.
